# Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Study · id `cardio:ct-nct02738632` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02738632](<https://clinicaltrials.gov/study/NCT02738632>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02738632

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 300 participants.

## Technical summary

Registry record NCT02738632. Randomized; double masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT02738632, source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02738632, source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)
- Primary completion: 2016-08 (actual) (ClinicalTrials.gov record NCT02738632, source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)
- Completion: 2016-08 (actual) (ClinicalTrials.gov record NCT02738632, source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02738632, source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02738632-2016-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
- Condition: Essential Hypertension
- Intervention (Drug): Telmisartan/Amlodipine+Hydrochlorothiazide
- Intervention (Drug): Telmisartan/Amlodipine
- Intervention (Drug): Placebo for Hydrochlorothiazide
- Lead sponsor: IlDong Pharmaceutical Co Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: IlDong Pharmaceutical Co Ltd (`cardio:org-ildong-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study (`cardio:pubmed-29248384`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6603a278f607b5a37f618f3a1c3669ad9fc3291a37fea4d5ad0d4ee6114a114c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
